Clinical trials: LGI1 Autoimmune Encephalitis
Autoimmune Encephalitis
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
Prospective cohort study evaluating FDG PET in 56 patients with confirmed autoimmune encephalitis - based on 2016 Graus criteria, and 2021 paraneoplastic neurological syndromes criteria - at the acute phase, before…
- Trial name
- ENCEPHATAIP (NCT06079294)
- Testing
- FDG PET
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Autoimmune Encephalitis
BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis
The term "autoimmune encephalitis" denotes an heterogenous group of diseases commonly associated with autoantibodies targeting neural or glial antigens.
- Trial name
- LGI1-IRM (NCT05825690)
- Testing
- Retrospective evaluation of specific brain MRI features
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Hospices Civils de Lyon
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
The main objective is to explore the efficacy and safety of Telitacicept in the treatment of refractory/recurrent anti-NMDAR and anti-LGI1 encephalitis.
- Trial name
- NCT06510283
- Testing
- Taitacept
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Tongren Hospital
Autoimmune Encephalitis, LGI1 Encephalitis
Relapse and Functional Outcomes in Anti-LGI1 Encephalitis
This study focuses on a rare brain disease called anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis. In this condition, the body's immune system mistakenly attacks a protein in the brain, which can cause problems with…
- Conditions
- Autoimmune Encephalitis, LGI1 Encephalitis, Limbic Encephalitis
- Trial name
- NCT07722286
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Shen Chun-Hong
Autoimmune Encephalitis
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
Autoimmune Encephalitis is a disorder of the central nervous system caused by bodily substances, called antibodies. Antibodies normally help the body to prevent infections.
- Trial name
- Generate-Boost (NCT03993262)
- Testing
- Bortezomib
- Where
- 17 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Jena University Hospital
Autoimmune Encephalitis, Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis.
- Trial name
- NCT06173076
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shen Chun-Hong
NMDAR Autoimmune Encephalitis, LGI1 Antibody Associated Encephalitis
Medium-term Effects of Treatments in Autoimmune Encephalitis
Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence.
- Conditions
- NMDAR Autoimmune Encephalitis, LGI1 Antibody Associated Encephalitis, CASPR2-Antibody, IgLON5
- Trial name
- META (NCT07133113)
- Testing
- We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Neuropsychiatric Symptom
Dissecting Immunological and Autoimmune Mechanisms of Neuropsychiatric Diseases
The goal of this observational cohort study is to investigate the role of immune system in neuropsychiatric symptoms (NPS) and to identify immunological biomarkers that may improve the diagnosis, prognosis, and future treatment…
- Trial name
- DIAMOND (NCT07791212)
- Where
- 2 sites in United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- King's College London
Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
The purpose of the study is to assess the efficacy of rozanolixizumab as measured by seizure freedom, change in cognitive function, use of rescue medication, onset of seizure freedom and to assess safety and tolerability.
- Trial name
- NCT04875975
- Testing
- Rozanolixizumab
- Where
- 27 sites in United States, Australia and 7 more
- Volunteers
- 12 people
- Sponsor
- UCB Biopharma SRL
Limbic Encephalitis With LGI1 Antibodies
Antibody-mediated LGI1 Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Chronic Phase of the Disease
The encephalitis mediated by antibodies against Leucine-rich, glioma inactivated 1 protein (anti-LGI1 encephalitis) predominantly affects men (M:F, 6:4) and mostly older than 60 years.
- Trial name
- NCT06515106
- Testing
- Remote cognitive rehabilitation program
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Optic Neuritis, Transverse Myelitis
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland.
- Conditions
- Optic Neuritis, Transverse Myelitis, Acute Disseminated Encephalomyelitis, Multiple Sclerosis
- Trial name
- NCT05017142
- Where
- 13 sites in Switzerland
- Volunteers
- 500 people
- Sponsor
- University of Bern
NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
- Trial name
- Cielo (NCT05503264)
- Testing
- Satralizumab
- Where
- 56 sites in United States, Argentina and 13 more
- Volunteers
- 122 people
- Sponsor
- Hoffmann-La Roche